Current status of liver diseases in Korea: Hepatitis A

2009 ◽  
Vol 15 (Suppl 6) ◽  
pp. S7 ◽  
Author(s):  
So Young Kwon
2001 ◽  
Vol 12 (6) ◽  
pp. 341-344 ◽  
Author(s):  
Jun Wu ◽  
Shimian Zou ◽  
Antonio Giulivi

Hepatitis A, caused by the hepatitis A virus, occurs most frequently in developing countries, but also causes sporadic cases or outbreaks in industrialized countries. The most common route of transmission is fecal-oral. The incidence of hepatitis A varies with geography, and economic and environmental conditions. The epidemiological pattern of the disease has changed with improvements in hygiene and economic conditions. The incidence and prevalence of hepatitis A has decreased, while the average age of exposure and subsequent infection has increased. The present report describes the current status of hepatitis A in Canada. The incidence rate of reported cases in Canada varies from over 10/100,000 (1991) to 3.6/100,000 (1998), and is higher in males, 4.7/100,000 (1998), than in females, 2.5/100,000 (1998). The highest reported hepatitis A rates are in age groups 30 to 39 years and 40 to 59 years, and in British Columbia. Such information is important for assessing current immunization approaches and for decision-making about new preventive strategies against hepatitis A in Canada.


Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1865 ◽  
Author(s):  
Kenya Kamimura ◽  
Takeshi Yokoo ◽  
Hiroyuki Abe ◽  
Shuji Terai

The liver is a key organ for metabolism, protein synthesis, detoxification, and endocrine function, and among liver diseases, including hepatitis, cirrhosis, malignant tumors, and congenital disease, liver cancer is one of the leading causes of cancer-related deaths worldwide. Conventional therapeutic options such as embolization and chemotherapy are not effective against advanced-stage liver cancer; therefore, continuous efforts focus on the development of novel therapeutic options, including molecular targeted agents and gene therapy. In this review, we will summarize the progress toward the development of gene therapies for liver cancer, with an emphasis on recent clinical trials and preclinical studies.


2014 ◽  
Vol 15 (5) ◽  
pp. 7500-7512 ◽  
Author(s):  
Philipp Uhl ◽  
Gert Fricker ◽  
Uwe Haberkorn ◽  
Walter Mier

2012 ◽  
Vol 1 (3) ◽  
pp. 299-305
Author(s):  
Ahmed M. El-Gohary ◽  
Fadia M. Attia ◽  
Fawzy A. Khalil

2011 ◽  
Vol 1 (3) ◽  
pp. 299-305
Author(s):  
Ahmed M. El-Gohary ◽  
Fadia M. Attia ◽  
Fawzy A. Khalil

Kanzo ◽  
2015 ◽  
Vol 56 (7) ◽  
pp. 366-368 ◽  
Author(s):  
Yoshinori Horie ◽  
Hirotoshi Ebinuma ◽  
Masahiro Kikuchi ◽  
Nobuhiro Nakamoto ◽  
Takanori Kanai

Sign in / Sign up

Export Citation Format

Share Document